Chronic Hepatitis B Infection Clinical Trial
Official title:
The Changes of Treg Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B
Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation, while Nucleoside analog(ue) drugs only inhibit viral replication. In hepatitis B infection, Treg cells Regulatory T cells played a negative role in immune. This study was aimed at investigating the changes of Treg cells frequency and function, and the expression of costimulatory molecules during Peg-IFN-αand nucleoside analog(ue) therapy.Meanwhile, the investigators wanted to verify whether Peg-IFN-α suppressed the virus, which led to the decline of Treg cells frequency and function;negative regulation of Tregs for immune cells diminished, hence, the function of immune cells recovered.
Pegylated interferon α-2a(Peg-IFN-α)and Nucleoside analog(ue) drugs can inhibit viral replication , but Peg-IFN-α also play an important role in immune regulation . In hepatitis B infection, Treg cells play an important role in immune regulation.Peg-IFN-α recommended as the first-line treatment has a higher chance to achieve HBeAg seroconversion and even HBsAg disappearance than nucleoside analog(ue) drugs, which may be related to the functional activation of Treg cells in the case of hepatitis and the function enhancement of Treg cells during Peg-IFN-α therapy. This study was aimed at investigating the changes of Treg cells frequency and function, and the expression of costimulatory molecules during Peg-IFN-αand nucleoside analog(ue) therapy.Meanwhile, the investigators wanted to verify whether Peg-IFN-α suppressed the virus, which led to the decline of Treg cells frequency and function;negative regulation of Tregs for immune cells diminished, hence, the function of immune cells recovered. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03329820 -
Quality of Life and Health Utility of Patients With CHB Infections
|
N/A | |
| Recruiting |
NCT04030039 -
Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention
|
||
| Recruiting |
NCT03209037 -
The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy
|
Phase 4 | |
| Recruiting |
NCT03210467 -
The Changes of Plasmacytoid Dendritic Cells Frequency and Function During Antiviral Therapy
|
N/A | |
| Recruiting |
NCT03210506 -
The Changes of Cytokines During Antiviral Therapy
|
N/A | |
| Recruiting |
NCT03209011 -
The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy
|
Phase 4 | |
| Recruiting |
NCT03208998 -
The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy
|
Phase 4 | |
| Recruiting |
NCT04638439 -
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
|
Phase 1 | |
| Recruiting |
NCT03587467 -
Study on Gut Microbiota in Chronic HBV Infected Patients
|
||
| Completed |
NCT05355467 -
Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum
|
Phase 4 | |
| Recruiting |
NCT04135235 -
Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B
|